{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:50:45Z","timestamp":1761630645859,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.annder.2013.02.023","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T02:51:24Z","timestamp":1365216684000},"page":"353-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effets ind\u00e9sirables cutan\u00e9s et retentissement sur la qualit\u00e9 de vie des inhibiteurs de mTOR au cours du traitement du cancer du rein"],"prefix":"10.1016","volume":"140","author":[{"given":"C.","family":"Voilliot-Trotot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Granel-Brocard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Geoffrois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tr\u00e9chot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Nguyen-Thi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Schmutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Barbaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2013.02.023_bib0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2013.02.023_bib0010","first-page":"177","article-title":"Version fran\u00e7aise du Skindex (Skindex-France). Adaptation et \u00e9valuation des propri\u00e9t\u00e9s psychom\u00e9triques","volume":"130","author":"Lepl\u00e8ge","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2013.02.023_bib0015","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.02.023_bib0020","first-page":"509","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2013.02.023_bib0025","series-title":"Manifestations cutan\u00e9es des th\u00e9rapies cibl\u00e9es anticanc\u00e9reuses","first-page":"71","article-title":"Manifestations dermatologiques des inhibiteurs de mTOR","author":"Giacchero","year":"2010"},{"key":"10.1016\/j.annder.2013.02.023_bib0030","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3\u00a0trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2013.02.023_bib0035","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.02.023_bib0040","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2\u00a0study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2013.02.023_bib0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"Sonis","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2013.02.023_bib0050","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.02.023_bib0055","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2013.02.023_bib0060","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejca.2011.11.028","article-title":"The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis","volume":"48","author":"Gomez-Fernandez","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2013.02.023_bib0065","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","article-title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","volume":"95","author":"Duran","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annder.2013.02.023_bib0070","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/cncr.25928","article-title":"A phase 2\u00a0study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2\u00a0consortium (P2C)","volume":"117","author":"Okuno","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2013.02.023_bib0075","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2\u00a0study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2013.02.023_bib0080","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.02.023_bib0085","first-page":"1","article-title":"Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors","volume":"21","author":"Balagula","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2013.02.023_bib0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.anplas.2012.02.002","article-title":"Toxicit\u00e9 dermatologique des nouvelles th\u00e9rapies cibl\u00e9es anticanc\u00e9reuses utilis\u00e9es en oncodermatologie","volume":"57","author":"Sibaud","year":"2012","journal-title":"Ann Chir Plast Esthet"},{"key":"10.1016\/j.annder.2013.02.023_bib0095","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000338893","article-title":"Onychopathy induced by temsirolimus, a Mammalian target of rapamycin inhibitor","volume":"224","author":"Peuvrel","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2013.02.023_bib0100","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.02.023_bib0105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2340\/00015555-1097","article-title":"Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors","volume":"91","author":"Sibaud","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2013.02.023_bib0110","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.TP.0000151630.25127.3A","article-title":"Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy","volume":"79","author":"Mah\u00e9","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.annder.2013.02.023_bib0115","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/sj.jid.5701142","article-title":"Critical review of generic and dermatology-specific health-related quality of life instruments","volume":"127","author":"Both","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2013.02.023_bib0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1477-7525-8-40","article-title":"Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study","volume":"8","author":"Andreis","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.annder.2013.02.023_bib0125","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2011.01.002","article-title":"Toxicities of targeted therapy and their management in kidney cancer","volume":"59","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196381300553X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196381300553X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:00:23Z","timestamp":1758970823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S015196381300553X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S015196381300553X"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2013.02.023","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets ind\u00e9sirables cutan\u00e9s et retentissement sur la qualit\u00e9 de vie des inhibiteurs de mTOR au cours du traitement du cancer du rein","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2013.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}